Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition

• Päätekijät: Hisham A. Badreldin (Tekijä), Nada Alsuhebany (Tekijä), Mohammed Alzahrani (Tekijä), Abdulmajeed M. Alshehri (Tekijä), Maha Aldoughaim (Tekijä), Saleh Alqifari (Tekijä), Omar Yassin (Tekijä), Lama Alfehaid (Tekijä), Tariq Alqahtani (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Elsevier, 2024-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Direct Oral Anticoagulants (DOACs) have revolutionized the treatment of thromboembolic disorders, offering targeted, effective, and safer alternatives to traditional anticoagulants like heparins and vitamin K antagonists (VKAs). Despite their benefits, DOACs have drawbacks, including an increased ri...